Hepatitis a disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HPT003 MIFTS: 67	Hepatitis a Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a ¹² ⁷⁶ ⁴³ ⁴⁴ ¹⁵ ⁷³

Viral Hepatitis, Type a ¹²

Viral Hepatitis a ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Liver diseases Endocrine diseases Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Certain infectious and parasitic diseases

Viral hepatitis

Acute hepatitis A

Hepatitis A with hepatic coma

Hepatitis A without hepatic coma

External Ids:

Disease Ontology ¹² DOID:12549

MeSH ⁴⁴ D006506

NCIt ⁵⁰ C3096

SNOMED-CT ⁶⁸ 40468003

ICD10 ³³ B15.0 B15.9

UMLS ⁷³ C0019159

Sources

Summaries for Hepatitis a

MedlinePlus : ⁴³ Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and liver disease, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Influenza A. The drugs Intron A and Cefazolin and Dextrose USP have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : ¹² A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : ⁷⁶ Hepatitis A is an infectious disease of the liver caused by the hepatitis A virus (HAV). Many cases have... more...

Sources

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus	Autoimmune Hepatitis
Hepatitis B	Hepatitis a
Hepatitis C	Viral Hepatitis
Hepatitis D	Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)

#	Related Disease	Score	Top Affiliating Genes
1	hepatitis	32.1	AFP F2 GPT HAVCR1 HAVCR2 MAVS
2	liver disease	30.9	ABCB7 AFP ALB F2 GPT SEPSECS
3	cutaneous leishmaniasis	30.7	IFNG IL10 TNF
4	autoimmune hepatitis	30.5	F2 GPT SEPSECS
5	acute liver failure	30.3	ALB F2 GPT
6	infantile liver failure syndrome 1	30.3	ALB F2 GPT
7	viral infectious disease	30.2	GPT IFNG IL10 MAVS TNF
8	alcoholic hepatitis	30.2	ALB F2 GPT IL10 TNF
9	hepatitis d	30.1	F2 GPT
10	typhoid fever	30.1	ALB F2 IFNG TNF
11	hepatitis e	30.1	ALB F2 GPT IFNG TNF
12	hepatitis c	29.9	GPT IFNG MAVS TNF
13	cholecystitis	29.9	ALB F2 GPT
14	viral hepatitis	29.9	ABCB7 AFP ALB F2 GPT SEPSECS
15	hepatitis b	29.9	AFP ALB F2 GPT IFNG TNF
16	liver cirrhosis	29.5	AFP ALB F2 GPT
17	hemophagocytic lymphohistiocytosis	29.5	IFNG IL10 TNF
18	hepatic coma	29.5	ALB F2 GPT
19	malaria	29.4	ALB HAVCR2 IFNG IL10 TNF
20	pertussis	29.4	IL10 TICAM1 TNF
21	epstein-barr virus hepatitis	29.3	ALB F2
22	celiac disease 1	29.3	ALB IFNG IL10 TNF
23	kawasaki disease	29.3	ALB IL10 TNF
24	plasmodium falciparum malaria	29.3	IFNG IL10 TNF
25	cholangitis	29.3	ALB F2 GPT TNF
26	multifocal choroiditis	29.2	IL10 TNF
27	choroiditis	29.2	IL10 TNF
28	bilirubin metabolic disorder	29.2	ALB F2 GPT
29	ulcerative colitis	29.2	IFNG IL10 TNF
30	colitis	29.2	IFNG IL10 TNF
31	primary biliary cirrhosis	29.2	ALB F2 SEPSECS
32	allergic rhinitis	29.2	HAVCR1 IFNG IL10
33	scrub typhus	29.2	GPT IL10 TNF
34	leptospirosis	29.2	F2 IFNG IL10 TNF
35	immunodysregulation, polyendocrinopathy, and enteropathy, x-linked	29.1	IFNG IKBKG IL10
36	poliomyelitis	29.1	IFNG IL10 TNF
37	aseptic meningitis	29.1	IFNG IL10 TNF
38	connective tissue disease	29.1	IFNG IL10 TNF
39	brucellosis	29.1	IFNG IL10 TNF
40	human immunodeficiency virus infectious disease	29.1	IFNG IL10 TNF
41	cholangitis, primary sclerosing	29.1	ALB GPT SEPSECS
42	graft-versus-host disease	29.1	IFNG IL10 TNF
43	demyelinating disease	29.1	IFNG IL10 TNF
44	rheumatic disease	29.0	IFNG IL10 TNF
45	chronic graft versus host disease	29.0	ALB IFNG IL10 TNF
46	meningitis	29.0	ALB IFNG IL10 TNF
47	asthma	28.9	F2 HAVCR1 IFNG IL10 TNF
48	dengue hemorrhagic fever	28.8	ALB F2 IFNG IL10 TNF
49	gastrointestinal system disease	28.6	AFP ALB F2 IFNG IL10 TNF
50	hemorrhagic fever	28.6	ALB F2 GPT IFNG IL10 TNF

Graphical network of the top 20 diseases related to Hepatitis a:

Sources

Symptoms & Phenotypes for Hepatitis a

Symptoms:

¹²

• fever
• vomiting
• fatigue
• abdominal pain
• jaundice

• nausea
• joint pain
• loss of appetite
• clay-colored bowel movements

UMLS symptoms related to Hepatitis a:

nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.97	ABCB7 F2 IFNG IKBKG IL10 MAVS
2	homeostasis/metabolism	MP:0005376	9.96	ABCB7 AFP ALB F2 IFNG IKBKG
3	digestive/alimentary	MP:0005381	9.92	ALB F2 IFNG IKBKG IL10 MAVS
4	liver/biliary system	MP:0005370	9.76	ABCB7 AFP ALB IFNG IKBKG IL10
5	mortality/aging	MP:0010768	9.7	ABCB7 AFP ALB F2 HAVCR2 IFNG
6	neoplasm	MP:0002006	9.17	AFP ALB IFNG IKBKG IL10 TICAM1

Sources

Drugs & Therapeutics for Hepatitis a

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Intron A ¹⁸ ⁴⁹	INTERFERON ALFA-2B	Schering-Plough	December 1997/ December 1995/ March 1997
FDA Label: Intron A Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C Indications and Usage: ¹⁸ Hairy Cell Leukemia INTRONÂ® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOLÂ® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS). DrugBank Targets: ¹⁶ 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1 Mechanism of Action: ¹⁸ Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production Action: stimulation, induction (unspecified effects on oncogene expression) FDA: -
2	Cefazolin and Dextrose USP ¹⁸	CEFAZOLIN SODIUM	B Braun Medical	July 2000
FDA Label: Cefazolin and Dextrose USP Disease/s that Drug Treats:Various bacterial infections, septicemia, endocarditis, and perioperative prophylaxis Indications and Usage: ¹⁸ Cefazolin for Injection USP and Dextrose Injection USP is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: Respiratory tract infections (1.1); urinary tract infections (1.2); skin and skin structure infections (1.3); biliary tract infections (1.4); bone and joint infections (1.5); genital infections (1.6); septicemia (1.7); endocarditis (1.8) and perioperative prophylaxis (1.9). DrugBank Targets: ¹⁶ Penicillin-binding protein 1A\|Penicillin-binding protein 1B\|Penicillin-binding protein 1C\|Penicillin-binding protein 2 Mechanism of Action: ¹⁸ Target: - Action: - FDA: Cefazolin is an antibacterial drug [see Microbiology (12.4)]. Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 858)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

93-14-1

3516

Methadone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

76-99-3

4095

Entecavir

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

142217-69-4

153941

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

104987-11-3

445643 439492

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

22916-47-8

4189

Emtricitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

143491-57-0

60877

Aluminum hydroxide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

21645-51-2

Neomycin

Approved, Vet_approved

Phase 4

1404-04-2

8378

Peginterferon alfa-2b

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

99210-65-8, 215647-85-1

Ribavirin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

36791-04-5

37542

Adefovir Dipivoxil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

142340-99-6

60871

Pyrazinamide

Approved, Investigational

Phase 4,Phase 2,Phase 3

98-96-4

1046

Isoniazid

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

54-85-3

3767

Rifampicin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

13292-46-1

5458213 5381226

Peginterferon alfa-2a

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

198153-51-4

5360545

Tocopherol

Approved, Investigational

Phase 4,Phase 3,Not Applicable

1406-66-2

14986

Telbivudine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

3424-98-4

159269

Lamivudine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

134678-17-4

60825

Ezetimibe

Approved

Phase 4,Phase 3,Phase 2,Phase 1

163222-33-1

150311

Pioglitazone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

111025-46-8

4829

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184

Metformin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

657-24-9

14219 4091

Ritonavir

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

155213-67-5

392622

leucovorin

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Amantadine

Approved

Phase 4,Phase 3,Phase 2

768-94-5

2130

Dopamine

Approved

Phase 4,Phase 3,Phase 2

51-61-6, 62-31-7

681

Prednisolone phosphate

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

302-25-0

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

50-24-8

5755

Methylprednisolone hemisuccinate

Approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

2921-57-5

Nitazoxanide

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

55981-09-4

41684

rituximab

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

174722-31-7

10201696

Ledipasvir

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1256388-51-8

67505836

Sofosbuvir

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

1190307-88-0

45375808

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

24280-93-1

446541

tannic acid

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Benzocaine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

94-09-7, 1994-09-7

2337

Ethiodized oil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

8008-53-5

Pentoxifylline

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

6493-05-6

4740

Chlorhexidine

Approved, Vet_approved

Phase 4,Not Applicable

55-56-1

2713 9552079

Ursodeoxycholic acid

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

128-13-2

31401

glycyrrhizin

Approved, Experimental

Phase 4,Phase 3,Phase 2

1405-86-3

3495

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

135968-09-1

Alprostadil

Approved, Investigational

Phase 4,Phase 2

745-65-3

149351 5280723

Simvastatin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

79902-63-9

54454

Zinc

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

7440-66-6

Insulin glulisine

Approved

Phase 4

207748-29-6

Insulin Glargine

Approved

Phase 4

160337-95-1

Ethanol

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

64-17-5

702

Acamprosate

Approved, Investigational

Phase 4

77337-76-9

71158

Interventional clinical trials:

(show top 50) (show all 4584)

#	Name	Status	NCT ID	Phase	Drugs
1	PCV13 + Hepatitis A Vaccine for Adults	Unknown status	NCT01926860	Phase 4
2	A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults	Unknown status	NCT02203357	Phase 4
3	Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders	Unknown status	NCT01126853	Phase 4
4	Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients	Unknown status	NCT02963714	Phase 4
5	Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients	Unknown status	NCT02991599	Phase 4
6	Immunogenicity of Hepatitis B Vaccination Among Drug Users	Unknown status	NCT02959775	Phase 4
7	Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma	Unknown status	NCT01765231	Phase 4	Entecavir prophylaxis;Observation arm
8	Adolescents' Response to Hepatitis B Vaccine Booster Dose	Unknown status	NCT01341275	Phase 4
9	Hepatitis C in Renal Transplant Recipients	Unknown status	NCT02108301	Phase 4	tacrolimus-cyclosporine A
10	Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients	Unknown status	NCT02327702	Phase 4	Emtricitabine
11	Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders	Unknown status	NCT01451801	Phase 4
12	Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment	Unknown status	NCT01724723	Phase 4	entecavir (BARACLUDE®)
13	Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta	Unknown status	NCT00117533	Phase 4	pegylated IFN alfa-2b plus ribavirin
14	Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation	Unknown status	NCT02417207	Phase 4	Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
15	Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy	Unknown status	NCT01341743	Phase 4	Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
16	Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)	Unknown status	NCT01311674	Phase 4
17	Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment	Unknown status	NCT01395654	Phase 4	isoniazid, rifampin, pyrazinamide
18	Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B	Unknown status	NCT01925820	Phase 4	Pegasys&Entecavir
19	Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT	Unknown status	NCT01833611	Phase 4	Entecavir;placebo
20	Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine	Unknown status	NCT01548326	Phase 4	Atorvastatin;placebo
21	Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues	Unknown status	NCT01911156	Phase 4	Continue NA treatment;Discontinue NA Treatment
22	Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients	Unknown status	NCT01148576	Phase 4	entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
23	Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B	Unknown status	NCT00597259	Phase 4	Pegasys plus Entecavir;Entecavir
24	Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients	Unknown status	NCT02327676	Phase 4	Emtricitabine
25	Emtricitabine for Naive Chinese Chronic Hepatitis B Patients	Unknown status	NCT02327663	Phase 4	Emtricitabine
26	Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)	Unknown status	NCT02745132	Phase 4
27	Twinrix Alternative Schedule Study	Unknown status	NCT00216229	Phase 4
28	Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis	Unknown status	NCT01998620	Phase 4	Ademetionine 2;Ademetionine 1;Ademetionine 3
29	Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy	Unknown status	NCT01595633	Phase 4	Switching from adefovir (10mg/day) to tenofovir (300mg/day)
30	Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues	Unknown status	NCT02362490	Phase 4	peginterferon alpha 2a
31	Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B	Unknown status	NCT02532413	Phase 4	Poly IC;Entecavir
32	Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection	Unknown status	NCT02973646	Phase 4	Entecavir or Tenofovir;Peginterferon Alfa-2B
33	Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study	Unknown status	NCT01804387	Phase 4	telbivudine plus adefovir;lamivudine plus adefovir
34	Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C	Unknown status	NCT01649245	Phase 4	Reiferon retard
35	The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection	Unknown status	NCT02412319	Phase 4	Anti-HBV placenta transfer factor injection
36	Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	Unknown status	NCT02768545	Phase 4	Ezetimibe
37	Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels	Unknown status	NCT00575627	Phase 4	Peg-Interferon alpha2a plus Ribavirin
38	Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients	Unknown status	NCT01439776	Phase 4
39	Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy	Unknown status	NCT01928511	Phase 4	peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
40	Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis	Unknown status	NCT02024295	Phase 4	Ademethionine;Polyene Phosphatidyl choline;Ademethionine
41	A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone	Unknown status	NCT00354653	Phase 4	LAMIVUDINE
42	Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B	Unknown status	NCT01906580	Phase 4	Peg-IFNα-2a;Entecavir
43	Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C	Unknown status	NCT02639585	Phase 4	Daclinza and Sunvepra
44	Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults	Unknown status	NCT02822547	Phase 4	Peginterferon alfa-2a
45	The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin	Unknown status	NCT01025765	Phase 4	Pioglitazone;Acarbose;Metformin
46	Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B	Unknown status	NCT02482272	Phase 4	Lamivudine;Adefovir;Entecavir
47	Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents	Unknown status	NCT02337127	Phase 4	Lamivudine
48	Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)	Unknown status	NCT01380951	Phase 4	telbivudine
49	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	NCT00834860	Phase 4	peginterferon alpha-2a and ribavirin
50	Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Unknown status	NCT01436539	Phase 4	Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Sources

Genetic Tests for Hepatitis a

Sources

Anatomical Context for Hepatitis a

MalaCards organs/tissues related to Hepatitis a:

⁴¹

Liver, Testes, Kidney, T Cells, Bone, B Cells, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

¹⁹

Liver

Sources

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 1720)

#	Title	Authors	Year
1	Outbreak of Hepatitis A Virus Infection Among Adult Patients of a Mental Hospital-Los Angeles County, 2017 - CORRECTION. ( 29970205 )		2018
2	Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels. ( 29371712 )	Lin W....Wei X.	2018
3	Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes. ( 29532736 )	Parker M....McGill N.W.	2018
4	Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )	Conteville L.C....Vicente A.C.P.	2018
5	Travel-associated hepatitis A in Europe, 2009 to 2015. ( 29871720 )	BeautAc J....Severi E.	2018
6	Hepatitis A, cardiomyopathy, aplastic anemia, and acute liver failure: A devastating scenario. ( 29359844 )	Botero V....Echeverri G.J.	2018
7	Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins? ( 29907320 )	Herzog C....Mayorga O.	2018
8	Duck hepatitis A virus structural proteins expressed in insect cells self-assemble into virus-like particles with strong immunogenicity in ducklings. ( 29426402 )	Wang A....Zhu S.	2018
9	Comparative liver transcriptome analysis in ducklings infected with duck hepatitis A virus 3 (DHAV-3) at 12 and 48A hours post-infection through RNA-seq. ( 29925406 )	Zhang X....Ma B.	2018
10	Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )	Fotos N.V....Brokalaki H.	2018
11	Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A. ( 29440324 )	Shin E.C....Jeong S.H.	2018
12	Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. ( 29904396 )	Lu F.B....Chen Y.P.	2018
13	Hepatitis A vaccination coverage among adolescents (13-17a8^years) in the United States, 2008-2016. ( 29449100 )	Nelson N.P....Elam-Evans L.D.	2018
14	The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. ( 29398275 )	Sun X....Levine H.	2018
15	Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. ( 29427580 )	Boettler T....Thimme R.	2018
16	A Case of Graves' Disease Accompanied with Acute Hepatitis A Virus Infection. ( 29943563 )	Hong S.E....Park C.K.	2018
17	Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis- A Multinational, Prospective, Controlled, Randomized Trial. ( 29385313 )	Sussman N....Kelly J.	2018
18	Pathogenicity of duck hepatitis A virus type 3 and innate immune responses of the ducklings to virulent DHAV-3. ( 29407574 )	Zhang X....Ma B.	2018
19	Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )	Yue X....Nelson N.P.	2018
20	Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C. ( 29846860 )	Davison J....Villalvazo Y.	2018
21	Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job? ( 29942730 )	Tajammal R....Nusrat S.	2018
22	Evidence of hepatitis A virus infection in the patients with acute encephalitis syndrome in Gorakhpur region, North India. ( 29895163 )	Joshi M.S....Chitambar S.D.	2018
23	Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )	Lee S.Y....Kim K.	2018
24	Experimental infection of Marmota monax with a novel hepatitis A virus. ( 29387970 )	Yu J.M....Duan Z.J.	2018
25	Relationship of Severity of Hepatitis A with Polymorphisms in Hepatitis A Virus Cellular Receptor 1 (HAVCR1) Gene. ( 29893695 )	Benjamin M....Aggarwal R.	2018
26	An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. ( 29380498 )	Ciccullo A....Di Giambenedetto S.	2018
27	Tumor Necrosis Factor-producing T-regulatory Cells AreA Associated With Severe Liver Injury in Patients With AcuteA Hepatitis A. ( 29229400 )	Choi Y.S....Shin E.C.	2018
28	Hepatitis A, B, and A/B vaccination series completion among US adults: a claims-based analysis. ( 29923789 )		2018
29	Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )		2018
30	Protective efficacy of a bivalent live attenuated vaccine against duck hepatitis A virus types 1 and 3 in ducklings. ( 29408021 )		2018
31	Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, the Netherlands, 2017. ( 29897040 )		2018
32	Group C Streptococcal Sore Throat with Hepatitis - a Rare Association. ( 29870104 )		2018
33	Response to comment on: Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. ( 29907321 )		2018
34	Improved TaqMan real-time assays for detecting hepatitis A virus. ( 29409997 )		2018
35	Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. ( 29324766 )		2018
36	Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study. ( 29885414 )		2018
37	HAVCR1 (CD365) and its mouse ortholog are functional hepatitis A virus (HAV) cellular receptors that mediate HAV infection. ( 29437974 )		2018
38	Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage. ( 29381561 )		2018
39	Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France. ( 29886426 )		2018
40	Leucopenia: A Rare Extrahepatic Manifestation of Acute Hepatitis A. ( 29892189 )		2018
41	Decrease in seroprevalence of hepatitis A virus in Santiago, Chile: A decade-long comparison. ( 29871761 )		2018
42	A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. ( 30194739 )	Kim JD...Kim YJ	2018
43	Outcome comparison of liver transplantation for hepatitis A-related versus hepatitis B-related acute liver failure in adult recipients. ( 29044729 )	Jung DH...Lee SG	2018
44	Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. ( 29632422 )	Buechter M...Kahraman A	2018
45	A Very Rare Complication of Hepatitis A Infection: Acute Myocarditis-A Case Report with Literature Review. ( 30302093 )	Allen O...Halalau A	2018
46	Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature. ( 29881634 )	Nango D...Echizen H	2018
47	Acute alcoholic hepatitis: a literature review and proposal of treatment. ( 29115798 )	Testino G...Leone S	2018
48	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. ( 29171941 )	Thompson J...VTI-208 Study Group	2018
49	Extracorporeal liver assist device for alcoholic hepatitis: A potential silver lining? ( 29365343 )	Morgan T	2018
50	Mortality and costs associated with alcoholic hepatitis: A claims analysis of a commercially insured population. ( 30048829 )	Thompson JA...Martinson M	2018

Sources

Genes for Hepatitis a

Genes related to Hepatitis a (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HAVCR1	Hepatitis A Virus Cellular Receptor 1	Protein Coding	68.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Proteins Functions Transcripts (show sections)
2	HAVCR2	Hepatitis A Virus Cellular Receptor 2	Protein Coding	44.33	GeneCards inferred via : Publications Gene name Proteins Transcripts (show sections)
3	TICAM1	Toll Like Receptor Adaptor Molecule 1	Protein Coding	25.6	GeneCards inferred via : Publications Proteins (show sections)
4	IKBKG	Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Gamma	Protein Coding	25.43	GeneCards inferred via : Publications Proteins (show sections)
5	F2	Coagulation Factor II, Thrombin	Protein Coding	24.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	ALB	Albumin	Protein Coding	24.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	22.66	DISEASES inferred ¹⁵ GeneCards inferred via : Proteins (show sections)
8	AFP	Alpha Fetoprotein	Protein Coding	22.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	TNF	Tumor Necrosis Factor	Protein Coding	22.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	22.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	ABCB7	ATP Binding Cassette Subfamily B Member 7	Protein Coding	21.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	IFNG	Interferon Gamma	Protein Coding	21.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	SEPSECS	Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase	Protein Coding	21.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	IL10	Interleukin 10	Protein Coding	21.06	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Hepatitis a

Sources

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Sources

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 31)

#	Super pathways	Score	Top Affiliating Genes
1	Toll-like Receptor Signaling Pathway ³⁷ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁷ NOD-like receptor signaling pathway ³⁷ NOD-like Receptor Signaling Pathways ⁶⁵ Regulation of toll-like receptor signaling pathway ¹	12.7	IFNG IKBKG IL10 MAVS TICAM1 TNF
2	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.6	IFNG IKBKG MAVS TICAM1 TNF
3	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ³⁷ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of RIG-I/MDA5 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ RIG-I-like Receptor Signaling ¹ RIG-I-like receptor signaling pathway ³⁷ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶ Virus Detection and Induction of Antiviral Signaling Pathways by RIG-I-like Receptors (RLR) ⁶⁵	12.56	IFNG IKBKG MAVS TICAM1 TNF
4	Immune response NFAT in immune response ²² Show member pathways Immune response CD28 signaling ²² Immune response ICOS pathway in T-helper cell ²² Immune response T cell receptor signaling pathway ²²	12.49	IFNG IKBKG IL10 TNF
5	Th17 cell differentiation ³⁷ Show member pathways IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.44	IFNG IKBKG IL10 TNF
6	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.28	IFNG IKBKG IL10 TNF
7	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.19	F2 IFNG IKBKG IL10 TNF
8	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.16	IFNG IKBKG TICAM1 TNF
9	Selenium Micronutrient Network ¹ Show member pathways Folate Metabolism ¹ Metabolism of ingested MeSeO2H into MeSeH ⁶⁶ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.16	ALB F2 IFNG TNF
10	Toxoplasmosis ³⁷ Show member pathways Leishmaniasis ³⁷	12.03	IFNG IKBKG IL10 TNF
11	Fluid shear stress and atherosclerosis ³⁷	11.96	IFNG IKBKG TNF
12	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ Th17 Differentiation Pathway ⁶⁵	11.92	IFNG IL10 TNF
13	Osteoclast differentiation ³⁷	11.91	IFNG IKBKG TNF
14	Microglia Activation During Neuroinflammation: Overview ⁶⁵ Show member pathways Microglia Activation During Neuroinflammation: Microglia Activation ⁶⁵	11.89	F2 IFNG TNF
15	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.85	IFNG IL10 TNF
16	Amoebiasis ³⁷	11.76	IFNG IL10 TNF
17	NF-kappa B signaling pathway ³⁷	11.75	IKBKG TICAM1 TNF
18	NF-kappaB Signaling ⁴	11.74	HAVCR1 HAVCR2 IFNG IKBKG IL10 MAVS
19	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.66	IFNG IL10 TNF
20	Pertussis ³⁷	11.63	IL10 TICAM1 TNF
21	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.59	IFNG IL10 TNF
22	Hepatitis C ³⁷	11.57	IKBKG MAVS TICAM1 TNF
23	Microglia Activation During Neuroinflammation: Microglia Polarization ⁶⁵	11.56	IFNG IL10 TNF
24	Cellular Transformation by HTLV1 ⁶⁴ Show member pathways Activation of NF-KappaB by PKR ⁶⁴	11.35	IFNG IKBKG TNF
25	Malaria ³⁷	11.3	IFNG IL10 TNF
26	FOXA2 and FOXA3 transcription factor networks ¹	11.22	AFP ALB F2
27	African trypanosomiasis ³⁷	11.04	IFNG IL10 TNF
28	EBV LMP1 signaling ¹	11.03	IKBKG TNF
29	IKK complex recruitment mediated by RIP1 ⁶⁶	11.03	IKBKG TICAM1
30	Canonical NF-kappaB pathway ¹	11	IKBKG TNF
31	Cytokines and Inflammatory Response ¹	10.59	IFNG IL10 TNF

Sources

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.17	AFP ALB F2 GPT IFNG IL10

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 31)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.82	IKBKG TICAM1 TNF
2	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.78	IL10 MAVS TNF
3	positive regulation of protein phosphorylation	GO:0001934	9.78	F2 IFNG MAVS TNF
4	response to virus	GO:0009615	9.77	IFNG IKBKG TNF
5	inflammatory response	GO:0006954	9.77	HAVCR2 IKBKG IL10 TICAM1 TNF
6	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	9.76	IKBKG MAVS TICAM1 TNF
7	cellular response to lipopolysaccharide	GO:0071222	9.73	HAVCR2 IL10 TICAM1 TNF
8	I-kappaB kinase/NF-kappaB signaling	GO:0007249	9.7	IKBKG TICAM1 TNF
9	TRIF-dependent toll-like receptor signaling pathway	GO:0035666	9.65	IKBKG TICAM1
10	protein import into nucleus, translocation	GO:0000060	9.65	IFNG TNF
11	positive regulation of osteoclast differentiation	GO:0045672	9.64	IFNG TNF
12	positive regulation of chemokine production	GO:0032722	9.63	HAVCR2 TNF
13	positive regulation of macrophage activation	GO:0043032	9.63	HAVCR2 IL10
14	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	9.62	IFNG TNF
15	negative regulation of growth of symbiont in host	GO:0044130	9.62	IL10 TNF
16	positive regulation of heterotypic cell-cell adhesion	GO:0034116	9.61	IL10 TNF
17	positive regulation of tumor necrosis factor secretion	GO:1904469	9.59	HAVCR2 MAVS
18	positive regulation of protein import into nucleus, translocation	GO:0033160	9.58	IFNG MAVS
19	MyD88-independent toll-like receptor signaling pathway	GO:0002756	9.58	IKBKG TICAM1
20	positive regulation of nitric oxide biosynthetic process	GO:0045429	9.58	IFNG TICAM1 TNF
21	toll-like receptor 3 signaling pathway	GO:0034138	9.57	HAVCR2 TICAM1
22	macrophage activation involved in immune response	GO:0002281	9.56	HAVCR2 TICAM1
23	endothelial cell apoptotic process	GO:0072577	9.55	IL10 TNF
24	positive regulation of chemokine biosynthetic process	GO:0045080	9.54	TICAM1 TNF
25	negative regulation of cytokine secretion involved in immune response	GO:0002740	9.51	IL10 TNF
26	positive regulation of myeloid dendritic cell cytokine production	GO:0002735	9.49	MAVS TICAM1
27	negative regulation of myeloid dendritic cell activation	GO:0030886	9.32	HAVCR2 IL10
28	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.26	IFNG TNF
29	receptor biosynthetic process	GO:0032800	9.16	IL10 TNF
30	positive regulation of vitamin D biosynthetic process	GO:0060557	8.96	IFNG TNF
31	negative regulation of interleukin-6 production	GO:0032715	8.8	HAVCR2 IL10 TNF

Sources

Sources for Hepatitis a

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia